42 citations
,
September 2000 in “British Journal of Dermatology”
This report describes two children with congenital hypotrichosis and found their short hair is due to a shortened anagenphase, with the condition resolving spontaneously during puberty.
16 citations
,
October 2003 in “Journal of The American Academy of Dermatology”
This study describes a 4-year-old boy who exhibits a rare, synchronized pattern of hair growth and shedding, unlike the typical asynchronous pattern seen in humans.
January 2012 in “Journal of Cosmetics, Dermatological Sciences and Applications”
This article discusses shortanagen syndrome, identifying it as a condition with a shorter anagenphase in hair follicles, but reports no new clinical results.
28 citations
,
June 2010 in “Pediatric dermatology”
This review discusses shortanagen syndrome, highlighting its symptom of abnormally short scalp hair without associated systemic diseases, and notes that hair length often improves spontaneously after puberty without treatment.
13 citations
,
March 2018 in “Pediatric Dermatology”
This review describes the clinical characteristics and confirms the diagnosis of shortanagen syndrome in the largest reported series to date, comparing it to loose anagen syndrome.
PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.
PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.
PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.